Narcolepsy Trials
Brilliance 302/304 (Narcolepsy Type 1)
Brilliance 303 (Narcolepsy Type 2)
Are you living with narcolepsy? You may be eligible to participate in a clinical research study evaluating a new investigational medication designed to improve wakefulness and reduce daytime sleepiness.
WHAT ARE THE BRILLIANCE STUDIES?
The BRILLIANCE Studies, sponsored by Alkermes, are Phase 3 clinical research studies evaluating an investigational medication called alixorexton (ALKS 2680) in adults with narcolepsy. The studies are designed for individuals diagnosed with:
Narcolepsy Type 1 (NT1)
Narcolepsy Type 2 (NT2)
Alixorexton is designed to activate the brain's orexin-2 receptor (OX2R). Orexin is a naturally occurring chemical in the brain that helps regulate the sleep-wake cycle and maintain wakefulness.
Researchers are studying whether activating this system can help people with narcolepsy stay awake during the day and improve symptoms that affect everyday life.
WHO MAY QUALIFY?
You may be eligible if you:
Are between 18 and 70 years of age.
Have a confirmed diagnosis of narcolepsy type 1 or type 2.
Experience excessive daytime sleepiness that affects your daily activities.
Have cataplexy that affects your daily activities (for NT1 participants).
Additional eligibility requirements apply. The research team will determine whether you qualify.
WHAT DOES PARTICIPATION INVOLVE?
Participation lasts approximately 22 weeks and includes three phases:
1. Screening (up to 8 weeks)
Health and medical history review.
Sleep testing, including an overnight sleep study (PSG) and Maintenance of Wakefulness Test (MWT).
A medication washout period of at least two weeks, during which current narcolepsy medications are discontinued under the supervision of the study team.
One required overnight stay at the research center.
2. Treatment (up to 12 weeks)
You will be randomly assigned to receive either alixorexton (the investigational medication) or a placebo (an inactive pill).
Two different active medication doses are being studied.
Two required overnight stays at the research center.
Regular study visits and assessments.
3. Follow-Up (2 weeks)
A final period of health and safety monitoring after treatment ends.
WHAT WILL RESEARCHERS BE MEASURING?
Researchers want to understand how the investigational medication may affect:
Wakefulness: Your ability to stay awake during the day.
Daytime sleepiness: How sleepy you feel during everyday activities.
Cataplexy: Frequency of episodes in participants with NT1.
Fatigue and cognition: How you feel physically and mentally, including attention and cognitive functioning.
Overall health and safety: Your well-being throughout the study.
Study assessments may include sleep studies, questionnaires, blood and urine tests, ECGs, physical examinations, and daily sleep and symptom diaries.
WHAT ARE THE POSSIBLE BENEFITS AND RISKS?
Participation may provide an opportunity to receive an investigational treatment and contribute to research that could help improve future treatment options for people living with narcolepsy.
However, personal benefit is not guaranteed, and you may receive a placebo rather than active medication.
Because alixorexton is investigational, its safety and effectiveness are still being studied. There may be risks or side effects that are not yet known. The research team will explain the known and potential risks before you decide whether to participate.
Xyrise Trial (Narcolepsy type 1 and 2)
PARTICIPATE IN THE XYRISE RESEARCH STUDY
Are you living with narcolepsy or idiopathic hypersomnia (IH)? You may be eligible to participate in a clinical research study evaluating expanded dosing options for Xywav.
This Phase 3 clinical research study is evaluating the effectiveness and safety of expanded Xywav dosing regimens in adults with narcolepsy or idiopathic hypersomnia.
Xywav is an FDA-approved medication. This study is investigating expanded dosing approaches, including once-nightly and twice-nightly dosing regimens.
WHO MAY QUALIFY?
You may be eligible if you:
Are between 18 and 75 years of age
Have a diagnosis of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), or idiopathic hypersomnia (IH)
Meet additional medication and symptom requirements, depending on your current or previous oxybate treatment
Medication-related screening considerations may include:
If you are not currently taking an oxybate medication, you must have clinically significant daytime sleepiness, generally reflected by an Epworth Sleepiness Scale (ESS) score greater than 11 at screening.
If you currently take an oxybate medication, your symptoms must have improved with treatment, and you must have been taking a stable total nightly dose of 3–9 grams for at least 2 months.
If you previously took an oxybate medication but are no longer taking it, you must have been off treatment for at least 2 weeks and must not have stopped because of intolerance, safety concerns, or lack of effectiveness.
Participants with NT1 must meet additional cataplexy-related requirements.
Other inclusion and exclusion criteria apply. A study physician will determine final eligibility.
WHAT DOES PARTICIPATION INVOLVE?
Participation includes three treatment periods and may involve up to approximately 16 weeks of study treatment, following screening and confirmation of eligibility.
1. Dose Titration and Optimization
Participants receive open-label Xywav.
Dosing is adjusted to identify a stable, appropriate regimen.
Participants are assigned to a once-nightly or twice-nightly dosing approach.
2. Stable Dose Period
Participants continue their established Xywav dose for an additional 2 weeks.
3. Double-Blind Randomized-Withdrawal Period
Participants are randomly assigned to either continue their stable Xywav dose or receive placebo for 2 weeks.
Neither participants nor the study team know the assigned treatment during this period.
Study visits, assessments, and safety monitoring will occur throughout participation.
WHAT IS THE STUDY EVALUATING?
Researchers are evaluating the effectiveness and safety of expanded Xywav dosing regimens, including:
Daytime sleepiness and related symptoms
The ability to maintain symptom control
Safety and tolerability of the study dosing regimens
Outcomes in participants with narcolepsy and idiopathic hypersomnia
IMPORTANT INFORMATION
Participation is voluntary. There is no guarantee of direct medical benefit. During the randomized-withdrawal period, participants may receive placebo instead of active study medication.
As with any medication, Xywav has potential risks and side effects. These will be reviewed with you by the study team before you decide whether to participate.
Contact the research team to discuss the study and whether you may qualify.
SAPPHIRE Study (Narcolepsy Type 1 and 2)
Are you living with narcolepsy? You may be eligible to participate in a clinical research study evaluating a new investigational medication designed to improve wakefulness and reduce daytime sleepiness.
WHAT IS THE SAPPHIRE STUDY?
The SAPPHIRE study (ORX750-004), sponsored by Centessa Pharmaceuticals, is evaluating an investigational medication called cleminorexton (ORX750) in adults diagnosed with:
Narcolepsy Type 1 (NT1)
Narcolepsy Type 2 (NT2)
Cleminorexton works by activating the brain's orexin system, which plays an important role in regulating wakefulness and the sleep-wake cycle. Researchers are studying whether activating this system can help people with narcolepsy stay awake during the day and improve their symptoms.
WHO MAY QUALIFY?
You may be eligible if you:
Are between 18 and 70 years old.
Have a diagnosis of narcolepsy type 1 or type 2.
Have significant daytime sleepiness (an Epworth Sleepiness Scale score of 12 or higher at baseline).
Are willing and able to discontinue your current narcolepsy medications under the direction of the study team.
Additional eligibility requirements apply. The research team will determine whether you qualify.
WHAT DOES PARTICIPATION INVOLVE?
Participation lasts up to approximately 20 weeks and includes three phases:
1. Screening (up to 7 weeks)
Review of your medical history and current medications.
Assessment of your narcolepsy symptoms and daytime sleepiness.
Sleep and wakefulness testing, including the Maintenance of Wakefulness Test (MWT).
Review of medication restrictions and any required medication washout.
Additional health and safety assessments to determine eligibility.
2. Treatment (12 weeks)
You will be randomly assigned to receive either cleminorexton (the investigational medication) or a placebo (an inactive pill).
Two active medication dose levels are being studied.
Neither you nor the study team will know which treatment you receive.
Study visits and assessments will monitor your symptoms, wakefulness, and overall health.
3. Safety Follow-Up (1 week)
A final assessment to monitor your health and safety after treatment ends.
Additional study visits: Participants should expect three overnight sleep-lab stays with next-day wakefulness testing: one at baseline, one at Week 4, and one at Week 12. Additional clinic visits will take place throughout the study.
WHAT WILL RESEARCHERS BE LOOKING AT?
Researchers want to understand how the investigational medication may affect:
Wakefulness: Your ability to stay awake during the day.
Daytime sleepiness: How sleepy you feel during everyday activities.
Narcolepsy symptoms: Including cataplexy in participants with NT1.
Overall health and safety: Your general well-being throughout the study.
WHAT ARE THE POSSIBLE BENEFITS AND RISKS?
Participation may provide an opportunity to access an investigational treatment and contribute to research that could benefit others living with narcolepsy. However, personal benefit is not guaranteed.
Because this medication is investigational, its safety and effectiveness are still being studied. Possible side effects identified in earlier research have included frequent urination, insomnia, dizziness, and headache. Additional risks may be identified as research continues.
ONSTRIDE-1 Trial (Narcolepsy type 1 and 2)
Participate in the ONSTRIDE-1 Trial
Are you living with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2)? You may be eligible to participate in a clinical research study evaluating a new formulation and dosing approach for pitolisant.
This Phase 3 clinical research study is evaluating the effectiveness and safety of HBS-301 in adults with narcolepsy. Researchers are studying its effects on excessive daytime sleepiness, cataplexy, wakefulness, and fatigue.
WHO MAY QUALIFY?
You may be eligible if you:
Are 18 years of age or older
Have a documented diagnosis of NT1 or NT2
Have excessive daytime sleepiness (EDS)
Have a qualifying narcolepsy diagnosis documented within the past 10 years
Medication-related considerations:
Certain wake-promoting medications and antidepressants may be permitted if taken at a stable dose for at least 3 months before screening.
Participants must be willing to maintain permitted medications at a stable dose during the blinded treatment period.
As-needed use of medications that may affect daytime sleepiness, including oxybates, stimulants, modafinil, and armodafinil, is not permitted.
Recent pitolisant use may affect eligibility.
Additional inclusion and exclusion criteria apply. A study physician will determine final eligibility.
WHAT DOES PARTICIPATION INVOLVE?
The study includes:
1. Screening and Baseline
Up to 28 days
Review of medical history and current medications
Confirmation of diagnosis and eligibility
Assessment of sleepiness and narcolepsy symptoms
Safety assessments
2. Double-Blind Treatment
8 weeks
Participants are randomly assigned to receive HBS-301 or placebo.
Neither participants nor the study team know which treatment is assigned.
Study visits and assessments monitor symptoms and safety.
3. Optional Open-Label Extension
Eligible participants may have the opportunity to receive open-label HBS-301 for up to 1 year.
4. Safety Follow-Up
30 days of safety follow-up after treatment.
WHAT IS THE STUDY EVALUATING?
Researchers are evaluating:
Excessive daytime sleepiness
Cataplexy symptoms
Wakefulness and ability to stay alert
Fatigue
Safety and tolerability of HBS-301
IMPORTANT INFORMATION
Participation is voluntary. Participants may receive HBS-301 or placebo during the 8-week treatment period. There is no guarantee of direct medical benefit.
Potential risks and side effects will be discussed with you by the study team before participation.
Contact the research team to discuss the study and whether you may qualify.
Interested? Email us at research@tricoastalsleep.com or click here.